micro-community-banner
 
  • Saved

1yr
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 - PubMed

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39094065/

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

LIBRETTO-001 study demonstrates durable, robust responses to selpercatinib in RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer, with high objective response rates and long-term progression-free survival.

  • Saved

1yr
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37870973/

Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov...

Selpercatinib significantly improved progression-free survival compared to platinum-based chemotherapy with or without pembrolizumab in advanced RET fusion-positive NSCLC, with similar safety profiles (ClinicalTrials.gov: NCT04194944).

  • Saved

1yr
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis - PubMed

Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37392903/

Comprehensive meta-analysis indicates a higher prevalence and incidence of BM in patients with certain targetable genomic alterations. This supports brain imaging at staging and follow-up, and the need for targeted...

The meta-analysis reveals increased brain metastasis prevalence and incidence in NSCLC patients with specific genomic alterations, highlighting the importance of brain imaging and brain-penetrant targeted therapies in managing these cases.

  • Saved

1yr
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - PubMed

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38118420/

The US Food and Drug Administration (FDA) approval of the selective RET inhibitors selpercatinib and pralsetinib has led to a paradigm change in the treatment of RET-altered lung and thyroid...

The FDA approval of selective RET inhibitors selpercatinib and pralsetinib revolutionizes RET-altered cancer treatment, offering high response rates and manageable toxicity, with broad potential across various tumor types.

  • Saved

1yr
Background Image DesktopBackground Image Mobile

Personalized precision medicine is central to modern healthcare, and Organoids-on-a-Chip (OoCs) represent a groundbreaking innovation. This review discusses how OoCs enhance patient-specific treatment by utilizing organoids for precise disease modeling, drug screening, and therapeutic individualization. It highlights the fusion of organoid culture with microfluidic technology, emphasizing its potential to transform healthcare through genomic medicine and ethical frameworks, ultimately improving patient outcomes and redefining treatment approaches.

Read More